Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 4/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033450 | 0.93 | LMNA (0.37) | SLC2A1NEK2PLK1ACACBPRKCA | |
| SCHEMBL4032062 | 0.91 | SLC2A1 (0.36) | SLC2A1NEK2PLK1MCHR1ACACB | |
| SCHEMBL3280568 | 0.88 | SRC (0.43) | SLC2A1NEK2PLK1RAB9ASRC | |
| SCHEMBL4032138 | 0.88 | PDE4D (0.38) | SLC2A1NEK2PLK1PRKCAPRKCD | |
| SCHEMBL3188070 | 0.83 | PRKCA (0.38) | ALDH1A1ACHEPRKCAPRKCDNPC1 | |
| SCHEMBL3431043 | 0.83 | PRKCA (0.41) | PRKCAPRKCDNPC1TP53RAB9A | |
| SCHEMBL3178090 | 0.82 | PRKCA (0.42) | PRKCAPRKCDNPC1TP53RAB9A | |
| SCHEMBL3429735 | 0.82 | CHRNB2 (0.38) | MCHR1ALDH1A1PRKCAPRKCDNPC1 | |
| SCHEMBL27221614 | 0.81 | PRKCA (0.38) | ALDH1A1PRKCAPRKCDNPC1TP53 | |
| SCHEMBL27221408 | 0.80 | PRKCA (0.37) | PLK1ALDH1A1PRKCAPRKCDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | SLC2A1 3970/4885NEK2 229/4885PLK1 77/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | SLC2A1 4136/4885NEK2 407/4885PLK1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.